China Shenghuo Pharmaceutical Holdings, Inc. (KUN) Reports Higher Sales of Xuesaitong in First Quarter of 2010
China Shenghuo Pharmaceutical Holdings, Inc. reported net income of $2,355 in the first quarter of 2010 compared to a net loss of $2.9 million in the first quarter of 2009. China Shenghuo Pharmaceutical Holdings, Inc. attributed the higher net income to improved sales of Xuesaitong, the company’s main drug product. Management also cited better control of operating expenses during the quarter. Gui Hua Lan, the CEO of China Shenghuo Pharmaceutical Holdings, Inc. said, “The increases in sales and net income were primarily due to the Company's continuous efforts to promote the sales of products and the efforts to control our…